Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Arqule Inc (ARQL)

Arqule Inc (ARQL)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 951,384
  • Shares Outstanding, K 120,734
  • Annual Sales, $ 25,760 K
  • Annual Income, $ -15,480 K
  • 60-Month Beta 2.31
  • Price/Sales 36.67
  • Price/Cash Flow N/A
  • Price/Book 6.00

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -0.10
  • Number of Estimates 4
  • High Estimate -0.10
  • Low Estimate -0.11
  • Prior Year -0.08
  • Growth Rate Est. (year over year) -25.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
6.98 +12.89%
on 11/06/19
10.35 -23.86%
on 11/01/19
-0.76 (-8.74%)
since 10/15/19
3-Month
6.79 +16.05%
on 09/30/19
10.35 -23.86%
on 11/01/19
-0.76 (-8.80%)
since 08/15/19
52-Week
2.23 +253.36%
on 12/21/18
12.22 -35.52%
on 07/05/19
+3.97 (+101.53%)
since 11/15/18

Most Recent Stories

More News
ArQule to Participate in the Jefferies London Healthcare Conference on November 20, 2019

ArQule, Inc. (Nasdaq: ARQL) today announced that Paolo Pucci, Chief Executive Officer, will participate in the Jefferies London Healthcare Conference on Wednesday, November 20, 2019 in London, UK.

ARQL : 7.88 (+0.70%)
ArQule Announces Release of American Society of Hematology Abstract Detailing Results of the Ongoing Phase 1 Study of Reversible BTK Inhibitor, ARQ 531, in Patients with Relapsed/Refractory Hematologic Malignancies

ArQule, Inc. (Nasdaq: ARQL) today announced the publication of the abstract highlighting data, as of July 19, 2019, from the phase 1 trial of ARQ 531, the company's potent and reversible dual inhibitor...

ARQL : 7.88 (+0.70%)
ArQule (ARQL) Reports Q3 Loss, Lags Revenue Estimates

ArQule (ARQL) delivered earnings and revenue surprises of 0.00% and -82.67%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

ARQL : 7.88 (+0.70%)
ArQule Reports Third Quarter 2019 Financial Results

ArQule, Inc. (Nasdaq: ARQL) today announced its financial results for the third quarter of 2019.

ARQL : 7.88 (+0.70%)
ArQule Presents Recent Data on ARQ 751 at the 2019 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

--Preclinical work demonstrates treatment with ARQ 751 in combination with a variety of therapeutic agents enhances anti-proliferative and anti-tumor activity

ARQL : 7.88 (+0.70%)
ArQule Announces Preclinical Data Demonstrating Potential of Miransertib (ARQ 092) to Treat PIK3CA-Driven Vascular Malformations at 2019 ASHG Annual Meeting

ArQule, Inc. (Nasdaq: ARQL), today announced preclinical data demonstrating the potential for miransertib (ARQ 092), it's pan-AKT inhibitor, to treat PIK3CA driven vascular malformations (VMs) in a poster...

ARQL : 7.88 (+0.70%)
ArQule to Report Third Quarter 2019 Financial Results on October 30, 2019

ArQule, Inc. (Nasdaq: ARQL) today announced it will report financial results for the third quarter of 2019 before the market opens on Wednesday, October 30, 2019. The Company will hold a conference call...

ARQL : 7.88 (+0.70%)
ArQule Announces Presentations on ARQ 751 at the 2019 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

ArQule, Inc. (Nasdaq: ARQL) today announced that it will be presenting data on the company's AKT inhibitor, ARQ 751, in two poster presentations at the 2019 AACR-NCI-EORTC International Conference on Molecular...

ARQL : 7.88 (+0.70%)
All You Need to Know About ArQule (ARQL) Rating Upgrade to Buy

ArQule (ARQL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

ARQL : 7.88 (+0.70%)
ArQule to Present Preclinical Data on Miransertib for the Treatment of Vascular Malformations at the 2019 American Society of Human Genetics (ASHG) Annual Meeting

ArQule, Inc. (Nasdaq: ARQL) today announced that it will be presenting research on the company's pan-AKT inhibitor, miransertib (ARQ 092), in a poster presentation at the 2019 ASHG Annual Meeting being...

ARQL : 7.88 (+0.70%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum.

See More Share

Trade ARQL with:

Business Summary

ArQule, Inc. is a biotechnology company engaged in the research and development of next-generation, small-molecule cancer therapeutics. The Company's targeted, broad-spectrum products and research programs are focused on key biological processes that are central to cancer. ArQule's lead clinical-stage...

See More

Key Turning Points

2nd Resistance Point 8.13
1st Resistance Point 8.00
Last Price 7.88
1st Support Level 7.70
2nd Support Level 7.53

See More

52-Week High 12.22
Fibonacci 61.8% 8.40
Last Price 7.88
Fibonacci 50% 7.23
Fibonacci 38.2% 6.05
52-Week Low 2.23

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar